Tirzepatide Vs. Semaglutide: Study Compares Cost And Health Outcomes In Obesity

In a caller study published successful the Journal of Medical Economics, a group of researchers evaluated nan cost-effectiveness of tirzepatide compared pinch semaglutide for adults pinch obesity aliases overweight successful nan United States (U.S.) utilizing a life simulation exemplary informed by nan SURMOUNT-5 head-to-head proceedings organization without type 2 glucosuria (T2D).

Obesity Costs and Long-Term Treatment Value

More than 70% of adults successful nan U.S. are overweight aliases person obesity, a information linked to superior wellness risks specified arsenic T2D, cardiovascular illness (CVD), and obstructive slumber apnea (OSA). These wellness risks trim value of life and besides create a important financial load for some nan individual and nan healthcare strategy arsenic a whole.

Fortunately, caller medications for illustration tirzepatide and semaglutide person changed nan scenery of weight management, offering important objective benefits; however, these medications travel astatine a precocious cost, raising nan mobility of whether that finance is worthwhile.

Therefore, an knowing of nan semipermanent economical worth of these medications is basal for patients, providers, and policymakers, and further studies are needed to measure their life cost-effectiveness.

SURMOUNT-5 Cost-Effectiveness Model Design

A patient-level simulation exemplary was developed to comparison tirzepatide and semaglutide utilizing information from nan SURMOUNT-5 Phase 3 objective trial. The simulated organization consisted of adults pinch obesity aliases overweight, defined arsenic a assemblage wide scale (BMI) of ≥30 kg/m² or≥27 kg/m² pinch astatine slightest 1 obesity-related complication. Age, sex, BMI, glycated hemoglobin (HbA1c), systolic humor unit (SBP), and lipid levels were derived from proceedings data.

The exemplary followed patients complete a life sky to bespeak nan chronic quality of obesity. Clinical outcomes were estimated by changes successful weight, HbA1c, cholesterol, and SBP. These factors influenced nan modeled consequence of processing complications specified arsenic T2D, CVD, metabolic dysfunction-associated steatotic liver illness (MASLD), and OSA.

Costs were analyzed from a U.S. societal perspective, including nonstop healthcare costs and indirect costs, specified arsenic mislaid productivity from absenteeism and presenteeism. Quality-adjusted life years (QALYs), which measurement some nan amount and value of life, were utilized to measurement wellness outcomes.

Incremental cost-effectiveness ratios (ICERs) and incremental nett wellness benefits (iNHBs) were calculated to comparison interventions. Sensitivity and script analyses were conducted to measure nan robustness of nan findings nether different assumptions.

The base-case study utilized publically available U.S. database prices, and further scenarios tested publically disposable nett prices.

Modeled Clinical and Economic Benefits of Tirzepatide

The study showed that tirzepatide provided some amended wellness outcomes and little wide costs compared to semaglutide. Over a lifetime, patients treated pinch tirzepatide were projected to incur costs that were $41,688 little per patient, while gaining an further 0.506 QALYs compared pinch patients receiving semaglutide, frankincense indicating some longevity and improved value of life successful nan model. The iNHB was besides affirmative for tirzepatide (0.784), which further supports its greater worth successful this analysis.

From a objective perspective, tirzepatide was projected to trim nan consequence of awesome obesity-related complications. For each 1,000 patients treated, 70 less cases of T2D and 10 less cases of CVD were modeled compared pinch semaglutide. These 2 factors, erstwhile combined, could person a important effect connected semipermanent outcomes. Chronic illness prevention straight affects regular functioning and reduces semipermanent aesculapian expenses.

In addition, tirzepatide provided importantly greater weight nonaccomplishment than semaglutide, an important constituent of improving a person's wide metabolic health. Those utilizing tirzepatide were overmuch much apt to return to normal humor glucose levels astatine 72 weeks, pinch 87.5% estimated to scope normoglycemia, compared pinch 76.88% for those receiving semaglutide.

With respect to slumber quality, tirzepatide was besides projected to trim nan incidence of OSA. Patients treated pinch semaglutide were estimated to walk 3.07 much years of their lives surviving pinch mean aliases much terrible OSA than did those receiving tirzepatide. As OSA is often associated pinch fatigue, reduced productivity, and accrued likelihood of accidents, this quality whitethorn beryllium important for some value of life and societal costs.

Economic benefits extended beyond healthcare costs, arsenic tirzepatide was associated pinch less mislaid workdays owed to illness, reducing some absenteeism and presenteeism. On average, patients treated pinch tirzepatide were projected to acquisition 5 less days of reduced productivity per year, highlighting broader societal advantages.

Importantly, these findings remained accordant crossed aggregate sensitivity and script analyses. Even erstwhile assumptions astir costs, curen persistence, and diligent subgroups varied, tirzepatide remained either cost-saving aliases highly cost-effective successful nan model.

Implications for Obesity Treatment Policy

Tirzepatide appears to beryllium a cost-effective action pinch favorable modeled objective outcomes compared to semaglutide for managing obesity and overweight successful nan U.S. In this simulation, tirzepatide was associated pinch greater weight loss, a little modeled consequence of processing chronic diseases specified arsenic T2D and CVD, and little projected costs than semaglutide.

As such, tirzepatide whitethorn connection important imaginable worth for patients, payers, and society, and nan findings item nan value of considering semipermanent worth alternatively than upfront supplier costs alone. 

As obesity continues to spot a awesome load connected wellness systems, medications that tin amended wellness outcomes while simultaneously decreasing nan costs of healthcare whitethorn power early healthcare argumentation and organization health.